AU5904896A - New variants of apolipoprotein A-I - Google Patents

New variants of apolipoprotein A-I

Info

Publication number
AU5904896A
AU5904896A AU59048/96A AU5904896A AU5904896A AU 5904896 A AU5904896 A AU 5904896A AU 59048/96 A AU59048/96 A AU 59048/96A AU 5904896 A AU5904896 A AU 5904896A AU 5904896 A AU5904896 A AU 5904896A
Authority
AU
Australia
Prior art keywords
apolipoprotein
new variants
variants
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU59048/96A
Other versions
AU717202B2 (en
Inventor
Gerd Assmann
Patrick Benoit
Eric Bruckert
Patrice Denefle
Nicolas Duverger
Jean-Charles Fruchart
Harald Funke
Gerald Luc
Gerard Turpin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Institut Pasteur de Lille
Aventis Pharma SA
Original Assignee
Universite Pierre et Marie Curie Paris 6
Rhone Poulenc Rorer SA
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie Paris 6, Rhone Poulenc Rorer SA, Institut Pasteur de Lille filed Critical Universite Pierre et Marie Curie Paris 6
Publication of AU5904896A publication Critical patent/AU5904896A/en
Application granted granted Critical
Publication of AU717202B2 publication Critical patent/AU717202B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU59048/96A 1995-05-22 1996-05-20 New variants of apolipoprotein A-I Ceased AU717202B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (en) 1995-05-22 1995-05-22 NEW VARIANTS OF APOLIPOPROTEIN
FR95/06061 1995-05-22
PCT/FR1996/000747 WO1996037608A1 (en) 1995-05-22 1996-05-20 Novel variants of apolipoprotein a-i

Publications (2)

Publication Number Publication Date
AU5904896A true AU5904896A (en) 1996-12-11
AU717202B2 AU717202B2 (en) 2000-03-23

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59048/96A Ceased AU717202B2 (en) 1995-05-22 1996-05-20 New variants of apolipoprotein A-I

Country Status (16)

Country Link
EP (1) EP0827538A1 (en)
JP (1) JPH11505712A (en)
KR (1) KR19990021828A (en)
AU (1) AU717202B2 (en)
BR (1) BR9608813A (en)
CA (1) CA2218759A1 (en)
CZ (1) CZ291376B6 (en)
FR (1) FR2734568B1 (en)
HU (1) HUP9802926A3 (en)
IL (1) IL118336A0 (en)
MX (1) MX9708727A (en)
NO (1) NO975367D0 (en)
SK (1) SK156397A3 (en)
TW (1) TW434260B (en)
WO (1) WO1996037608A1 (en)
ZA (1) ZA964097B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU2001245622A1 (en) * 2000-03-13 2001-09-24 Amgen Inc. Apo-a-i regulation of t-cell signaling
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
JP2005504085A (en) 2001-09-28 2005-02-10 エスペリオン セラピューティクス，インコーポレイテッド Prevention and treatment of restenosis by local administration of drugs
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
BR0310099A (en) 2002-05-17 2007-03-20 Esperion Therapeutics Inc method for treating dyslipidemia or a disease associated with dyslipidemia
EP1596828B1 (en) 2003-02-14 2011-12-28 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
JP2007531537A (en) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein AI and apolipoprotein A-IMLANO
KR100560102B1 (en) 2004-06-25 2006-03-13 한국생명공학연구원 Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia
US20060030525A1 (en) * 2004-07-23 2006-02-09 Xencor, Inc. Apolipoprotein A-I derivatives with altered immunogenicity
KR100725642B1 (en) * 2006-01-20 2007-06-07 충남대학교산학협력단 Peptides of antioxidant activities against low-density lipoprotein LDL
CN101489577B (en) 2006-06-01 2013-10-16 蒙特利尔心脏病学研究所 Method and compound for the treatment of valvular disease
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
MY188457A (en) * 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
SI2396017T1 (en) 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
CN103443123B (en) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 Lipoprotein complexes and their preparation and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.

Also Published As

Publication number Publication date
CZ291376B6 (en) 2003-02-12
CZ367197A3 (en) 1998-03-18
CA2218759A1 (en) 1996-11-28
HUP9802926A3 (en) 2001-08-28
FR2734568B1 (en) 1997-06-20
NO975367L (en) 1997-11-21
SK156397A3 (en) 1998-07-08
NO975367D0 (en) 1997-11-21
WO1996037608A1 (en) 1996-11-28
AU717202B2 (en) 2000-03-23
KR19990021828A (en) 1999-03-25
BR9608813A (en) 1999-02-17
MX9708727A (en) 1997-12-31
IL118336A0 (en) 1996-09-12
HUP9802926A2 (en) 1999-03-29
JPH11505712A (en) 1999-05-25
EP0827538A1 (en) 1998-03-11
TW434260B (en) 2001-05-16
FR2734568A1 (en) 1996-11-29
ZA964097B (en) 1996-12-06

Similar Documents

Publication Publication Date Title
AU5904896A (en) New variants of apolipoprotein A-I
AU4620396A (en) Direactive mesogenic compounds and intermediates
AU5893696A (en) Modification of polypeptides
AU7168696A (en) Inhibitors of regulatory pathways
AU6614696A (en) Inhibition of gene expression
AU6490396A (en) Substituted-pent-4-ynoic acids
AU4786496A (en) New forms of paroxetin hydrochloride
AU6535894A (en) Lipase variants
AU6614596A (en) Inhibition of gene expression
AU5893796A (en) Modification of polypeptides
AU7629496A (en) Truncated hepatocyte growth factor variants
AU696080B2 (en) Bisphenol ester derivatives
AU7271696A (en) Method of production of lovastatin
AU6040296A (en) Methods of inducing bef-1 transcription factor
AU4940296A (en) Genetic modification of plants
AU4224096A (en) Use of phenylcyclohexylcarboxamides
AU4679196A (en) Copolyetherester
AU4877196A (en) Derivatives of 3-pyrrolidylidene-2-one-cephalosporines
AU5440596A (en) Inhibiting degradation of a degron-bearing protein
AU1586295A (en) Modification of filamentous microorganisms
AU6993598A (en) Manufacture of alpha-tocopherol
AU7290096A (en) Substituted benzylidenecyanoacetic esters
AU5657596A (en) Composition of matter
AU6311296A (en) Selection of recombinant molecules
AU6516296A (en) Novel quinoxaline- and quinoxalinylalkane-phosphonic acids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)